MediciNova, Inc. — Q1 2012 Form 10-Q Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for serious diseases with unmet medical needs. The report covers the three months ended March 31, 2012, and was filed May 10, 2012. The company’s principal programs included MN-221 for acute asthma and COPD exacerbations and MN-166 for multiple sclerosis and other central nervous system disorders.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Revenue | $191,174 | $0 | New revenue from Kissei services |
| Research and development expense | $1.878 million | $2.624 million | Decreased $0.746 million |
| General and administrative expense | $2.186 million | $2.352 million | Decreased $0.166 million |
| Total operating expenses | $4.064 million | $4.976 million | Decreased $0.912 million |
| Operating loss | $3.873 million | $4.976 million | Improved $1.103 million |
| Net loss | $3.867 million | $5.656 million | Improved $1.789 million |
| Basic and diluted loss per share | $0.24 | $0.45 | Improved |
| Net cash used in operating activities | $3.427 million | $3.963 million | Improved $0.536 million |
Cash and cash equivalents were $11.006 million at March 31, 2012, versus $15.093 million at December 31, 2011. Total current assets were $11.804 million and total current liabilities were $2.742 million, implying working capital of approximately $9.062 million. Total assets were $26.913 million and total liabilities were $6.334 million.
The company had no debt or interest expense during the quarter. Its $15.0 million Oxford loan had been repaid in full on April 1, 2011. Deferred revenue totaled $2.309 million, consisting of $672,336 current and $1.636 million long-term. The company reported an accumulated development-stage deficit of $289.1 million.
Investing cash use was $688,024, primarily the $680,000 investment for a 30% interest in a China joint venture. Financing activities provided $27,889, principally from employee stock purchases. The company reported no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Revenue increased from zero to $191,174 as Kissei-related research and development services were performed under a $2.5 million non-refundable upfront-payment agreement.
- Research and development expense declined 28%, primarily because the MN-221 asthma trial approached completion.
- General and administrative expense declined 7%; lower bonuses, salaries, severance and professional fees were partly offset by a $0.5 million increase in stock-based compensation.
- Stock-based compensation increased to $927,291 from $175,683.
- Interest expense declined from $652,387 to zero following repayment of the Oxford debt.
- Cash decreased by $4.087 million during the quarter, compared with a $3.128 million increase in Q1 2011, reflecting ongoing operating cash burn and the China joint venture investment.
- In March 2012, the company funded its 30% China joint venture interest. The joint venture had not commenced operations, and the required MN-221 sublicense had not been executed.
Guidance, outlook, commentary, risks and unusual items
Management expected operating losses to continue for at least several years. It believed existing working capital would fund operations through at least March 31, 2013, assuming adherence to the current operating plan and no new clinical trials. Management also stated that additional equity or debt financing would likely be needed over time.
The 176-patient MN-221 Phase 2 asthma trial completed enrollment on March 21, 2012, with results expected in the second quarter of 2012. Results had not been determined as of the filing date. A new MN-221 Phase 1b/2a COPD trial began enrollment in the first quarter and was expected to complete around the end of the second quarter of 2012.
- Clinical-trial outcomes, regulatory approvals, development costs and the ability to secure partners or financing remain material uncertainties.
- If funding is insufficient, the company may delay, reduce or terminate development programs, potentially jeopardizing license rights.
- The China joint venture may not obtain the required sublicense or proceed with MN-221 development.
- A former employee’s claims were being handled through arbitration scheduled to begin September 17, 2012. Management did not expect a material adverse outcome, but acknowledged litigation could result in a material liability.
- Cash balances exceeded FDIC insurance limits, and money-market funds were not federally insured.
- No impairment indicators were identified for the $9.6 million goodwill balance or $4.8 million in-process research and development.
Important facts for investors to verify
- Timing and results of the MN-221 asthma Phase 2 trial and progress of the COPD trial.
- Actual cash burn and whether the stated cash runway through March 31, 2013 remains achievable.
- Future financing needs, dilution risk and any new debt or equity issuance.
- Execution of the MN-221 China sublicense and operational status of the joint venture.
- Recognition schedule for the remaining Kissei deferred revenue and the costs required to perform the related services.
- Potential financial impact of the pending employment arbitration and other litigation.
- Potential dilution from 3.09 million outstanding stock options, warrants and convertible Series B preferred stock.